Author + information
- Jae Yoon Park,
- Mohammed Al-Hijji,
- Abdallah El Sabbagh,
- Kebede H. Begna,
- Thomas M. Habermann,
- Thomas E. Witzig,
- Amir Lerman and
- Joerg Herrmann
Hematologic malignancies account for nearly 10% of new cancer diagnoses and cancer deaths in the U.S. The incidence, characteristics, and outcomes of acute coronary syndrome (ACS) in patients actively treated for these malignancies are not defined.
5300 consecutive patients with active hematologic malignancies hospitalized at Mayo Clinic Rochester were retrospectively reviewed for presence of ACS from 2004-2014. The primary outcomes were in-hospital and 1-year mortality.
73 patients (1.4%, demographics in Table) had ACS (78.1% non-ST-segment myocardial infarction (NSTEMI) and 13.7% STEMI). 17.5% and 40% of the NSTEMI and STEMI patients underwent coronary angiography with 5.3% and 30% PCI, respectively. Patients referred for catheterization had a higher hemoglobin level (10.3 vs. 9.0 g/dL; p<0.01) and platelet count (255,000 vs. 104,000 /mcL; p<0.05), and lower white blood cell count (11,800 vs. 57,000 /mcL; p<0.05). While > 80% of patients received beta-blocker, only around half received antiplatelet, anticoagulant, and/or statin therapy (Table). The in-hospital and 1-year mortality was 21.9% and 58.9%, respectively, of which 81.3% and 68.1% were non-cardiac in etiology (Table).
ACS in patients with active hematologic malignancies is not common but commonly managed non-aggressively in terms of medical therapy and catheterization referral. The leading cause of death in-hospital and within 1-year of ACS remains non-cardiac in nature.
Poster Area, South Hall A1
Sunday, April 03, 2016, 9:45 a.m.-10:30 a.m.
Session Title: Clinical and Therapuetic Factors Affecting Outcome After Acute Coronary Syndromes
Abstract Category: 14. Acute Coronary Syndromes: Clinical
Presentation Number: 1169-037
- 2016 American College of Cardiology Foundation